Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;1(6):1097-1100.
doi: 10.3892/ol.2010.193. Epub 2010 Sep 23.

Prediction and analysis of HLA-A2/A24-restricted cytotoxic T-lymphocyte epitopes of the tumor antigen MAGE-n using the artificial neural networks method on NetCTL1.2 Server

Xiu-Min Zhang  1 , Yang Huang, Zeng-Shan Li, Hui Lin, Yan-Fang Sui
Affiliations

Prediction and analysis of HLA-A2/A24-restricted cytotoxic T-lymphocyte epitopes of the tumor antigen MAGE-n using the artificial neural networks method on NetCTL1.2 Server

Xiu-Min Zhang et al. Oncol Lett. 2010 Nov.

Abstract

Cancer immunotherapy has become one of the most important therapeutic approaches to cancer in the past two decades. Tumor antigen-derived peptides have been widely used to elicit tumor-specific cytotoxic T lymphocytes (CTLs). Antigen-specific CTLs induced by MAGE-derived peptides have proven to be highly efficacious in the prevention and treatment of various types of tumor. MAGE-n is a new member of the MAGE gene family and has been shown to be closely associated with hepatocellular carcinoma. It is highly homologous to the MAGE-A gene subfamily, particularly to MAGE-3 (93%). MAGE-n-derived peptide QLVFGIEVV is a novel HLA-A2.1-restricted CTL epitope that induces MAGE-n-specific CTLs in vitro. Identification of these CTL epitopes may lead to clinical applications of these peptides as cancer vaccines for patients with MAGE-n(+)/HLA-A2(+) tumors. In the present study, HLA-A/A24-restricted CTL epitopes of antigen MAGE-n were predicted using the NetCTL1.2 Server on the web, COMB >0.85. The results showed that the NetCTL1.2 Server prediction method improved prediction efficacy and accuracy. Additionally, 8 HLA-A2- and 9 HLA-A24-restricted CTL epitope candidates (nonamers) derived from the tumor antigen MAGE-n were predicted. These nonamers, following identification via experimentation, may contribute to the development of potential antigen peptide tumor vaccines.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The web page of the NetCTL-1.2 Server epitope prediction.
See this image and copyright information in PMC

References

    1. Katsura F, Eura M, Chikamatsu K, Oiso M, Yumoto E, Ishikawa T. Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24. Jpn J Clin Oncol. 2000;30:117–121. - PubMed
    1. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995;2:167–175. - PubMed
    1. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 2001;50:3–15. - PMC - PubMed
    1. Wu W, Sui YF, Ye J, Li ZS, Guo AL, Yang XW, QU P, Zhang XM. The cloning of tumor-associated gene MAGE in human hepatocellular carcinoma cell line. Chin J Cell Mol Immunol. 2002;18:270–274.
    1. Ming LH, Zhu YR, Harris CC, Wang XH, Wu ZY, Sun ZT. Association of HLA-A02 genotype with hepatocellular carcinoma in a prevalent area of China. Chin J Immunol. 1999;15:305–310.